
Keywords: cost-effectiveness; heart failure; medications; ACEI; angiotensin-converting enzyme inhibitor; AldA; aldosterone antagonists; BB; beta-blocker; HF; heart failure; HFrEF; heart failure with reduced ejection fraction; ICER; incremental cost-effectiveness ra